Based on evidence for primary cilium functions in multiple cancers and the correlations between IFT57 expression and survival in several cancers [10,11,12,13], targeting the IFT57 and CD47 axes together may enhance the efficacy of the CD47-specific therapeutics currently in clinical trials. This evidence concerns the gene CD47 and cancer.